KangMa-Healthcode, since 2015, is a biomedical enterprise integrating DNA-to-Protein (D2P) core technology, Biomedical innovative product research and development, and Protein sequence intelligent algorithm. KansetinTM Blocking Protein is one of the industrialization achievements of KangMa D2P technology during the COVID-19 pandemic. KangMa has achieved large-scale protein synthesis, and is widely used in IVD, drug screening, biomedicine, public epidemic prevention, medical beauty, health and other fields.